Global Bipolar Disorder Therapeutic Market Research Report 2021

Bipolar disorder, also known as manic-depressive disorder, is a mental illness. It is a mental health problem that primarily affects mood. Symptoms of bipolar disorder are extreme irritability or agitation, a period of feeling empty, loss of interest in normal activities, sleep problems, etc. According to Pfizer, Inc., bipolar disorder affects over 5 million people in the U.S. Bipolar episodes are characterized by a drastic change in behavior and mood, and range from joyful and overexcited (manic episodes) to extremely sad and hopeless (depressive state). These disorders have different types of episodes such as manic episodes, hypomanic episodes, depressive episodes, and mixed episodes. Causes of bipolar disorders include childhood trauma, stressful life events, self-esteem problems, and genetic inheritance. People across the world marked “March 30” as a World Bipolar Day to spread awareness about the disorder and erase the stigma of mental illness. Large number of people suffering from this mental condition resort to drinking to lift their mood. According to the National Institute on Alcohol Abuse and Alcoholism, 27.6% of the people with bipolar disorder become addicted to alcohol, while over 16% engaged in alcohol abuse.
The growing need to reduce the financial burden of bipolar disorder will drive the growth prospects for the global bipolar disorder therapeutic market until the end of 2021. It has been observed that governments and companies across the globe are increasingly organizing awareness camps to raise disease awareness among the public, reduce the burden of mental disorders in vulnerable groups, ensure the rights of people with mental disorders, and make treatment facilities accessible to them. Consequently, such awareness initiatives help to curb the overall monetary loss, reduce their effect on the global economy, and improve the quality of life for patients. Such factors will raise public awareness about mental disorders and treatments and in turn, propel the rate of revenue generation in the market.

The global Bipolar Disorder Therapeutic market was valued at US$ 3855.3 million in 2019 and is expected to reach US$ 4443.3 million by the end of 2026, growing at a CAGR of 2.0% during 2021-2026.
This report focuses on Bipolar Disorder Therapeutic volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Bipolar Disorder Therapeutic market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Bipolar Disorder Therapeutic Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Antipsychotics
Anticonvulsants
Mood Stabilizers

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Eli Lilly
Bristol-Myers Squibb
AstraZeneca
Allergan
Astellas Pharma
GlaxoSmithKline
Janssen Pharmaceuticals

Frequently Asked Questions